KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stryker (SYK) Research & Development (2016 - 2025)

Stryker (SYK) has disclosed Research & Development for 17 consecutive years, with $401.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 12.01% to $401.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 10.71% increase, with the full-year FY2025 number at $1.6 billion, up 10.71% from a year prior.
  • Research & Development was $401.0 million for Q4 2025 at Stryker, down from $410.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $413.0 million in Q1 2022 to a low of $288.0 million in Q1 2021.
  • A 5-year average of $358.3 million and a median of $355.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 43.4% in 2022, then dropped 17.92% in 2023.
  • Stryker's Research & Development stood at $331.0 million in 2021, then dropped by 1.51% to $326.0 million in 2022, then grew by 7.36% to $350.0 million in 2023, then rose by 2.29% to $358.0 million in 2024, then increased by 12.01% to $401.0 million in 2025.
  • Per Business Quant, the three most recent readings for SYK's Research & Development are $401.0 million (Q4 2025), $410.0 million (Q3 2025), and $407.0 million (Q2 2025).